Is Fruquintinib included in medical insurance?

Fruquintinib (Fruquintinib) is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. It is limited to third-line treatment for patients with metastatic colorectal cancer. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. Its mechanism of action is mainly through inhibiting the activity of vascular endothelial growth factor receptor (VEGFR), where VEGFR includes VEGFR-1, VEGFR-2 and VEGFR-3. By interfering with the signaling pathways of these receptors, fruquintinib can inhibit the formation and growth of tumor blood vessels, thereby reducing the tumor's dependence on blood supply and achieving the effect of inhibiting tumor growth and spread.